KYNOS THERAPEUTICS LTD

S1 4HS (Yorkshire and The Humber)

Start Date

End Date Funded Value Relevance

CSV

25 50 100

£2,546,943

Mar 22 - Mar 24

Phase 1 Randomised Clinical Trial of the First-in-Class KMO inhibitor KNS366

Innovate UK award to KYNOS THERAPEUTICS LTD and Scott Webster

{{facetGroup.name}}

{{getFilterText(facet,showCount)}}